Hemodynamics, fluids & transfusion
The Efficacy and Safety of Angiotensin II for Treatment of Vasoplegia in Critically Ill Patients: A Systematic Review
Authors' conclusion
Despite unclear mortality impacts, angiotensin II seems to confer beneficial effects on several organ systems and RAS derangements, without increasing adverse events.
Study context
- Population
- Critically ill adults and children
- Participants
- 2,918 adults · 59 studies
- Comparison
- IV angiotensin II vs controls
- Outcome
- Mortality (comparative studies)
Pooled result
As reported in the abstract
- Mortality not different from controls in 14 comparative studies (5 randomized controlled trials (RCTs), 9 observational), except in 1 observational study
Further pooled results
Organ dysfunction
- Several studies reported decreased RRT use, improved oxygenation and BP response, and decreased myocardial injury with angiotensin II
Renin-angiotensin system (RAS) biomarkers
- Angiotensin II reduced renin and angiotensin I levels without affecting other RAS biomarkers
Safety
- No increase in thrombotic events or adverse events
Original publication
The Efficacy and Safety of Angiotensin II for Treatment of Vasoplegia in Critically Ill Patients: A Systematic Review. J Cardiothorac Vasc Anesth. Published 18 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →